These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25329929)

  • 1. Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort.
    Alroughani RA; Akhtar S; Ahmed SF; Al-Hashel JY
    Int J Neurosci; 2015; 125(11):831-7. PubMed ID: 25329929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
    Ramsaransing GS; De Keyser J
    Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
    Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
    Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical course of multiple sclerosis patients in Hong Kong.
    Lau KK; Wong WW; Sheng B; Yu IT; Fung BH; Li HL; Ma KF; Wong LK; Li PC
    J Neurol Sci; 2008 May; 268(1-2):78-82. PubMed ID: 18068191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
    Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
    Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
    D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
    Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.
    Alroughani R; Ashkanani A; Lamdhade S
    Int J Neurosci; 2012 Feb; 122(2):82-7. PubMed ID: 21985585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis.
    Alroughani R; Ahmed SF; Al-Hashel J
    Pediatr Neurol; 2015 Dec; 53(6):508-12. PubMed ID: 26383244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.
    Kantarci OH; Lebrun C; Siva A; Keegan MB; Azevedo CJ; Inglese M; Tintoré M; Newton BD; Durand-Dubief F; Amato MP; De Stefano N; Sormani MP; Pelletier D; Okuda DT
    Ann Neurol; 2016 Feb; 79(2):288-94. PubMed ID: 26599831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome.
    Sandi D; Biernacki T; Szekeres D; Füvesi J; Kincses ZT; Rózsa C; Mátyás K; Kása K; Matolcsi J; Zboznovits D; Burány Z; Langane É; Vécsei L; Bencsik K
    Mult Scler Relat Disord; 2017 Oct; 17():57-62. PubMed ID: 29055476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.
    Usta NC; Boz C; Terzi M
    Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
    Achiron A; Barak Y; Rotstein Z
    Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.